Skip to main content

Dr. Patrick R. Oellers, MD

Retina Specialist (Retina Specialist (Ophthalmology) Physician)

  • Medicare participating

At a glance

Years since graduation
16
In the NPI registry since
2012
Medicare patients seen, 2024
1,161

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2012Registered with an NPI (national billing number; not a license date)

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Retina Specialist (Ophthalmology) Physician primary
    NY license 293024

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Retina Specialist per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
1,161
Services billed
46,916
Patients’ average age
77
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, faricimab-svoa, 0.1 mg7,86016
Injection, aflibercept, 1 mg3,506308
Imaging of retina3,3391,025
Injection of drug into eye1,958385
Injection, ranibizumab, 0.1 mg1,47458
Injection, pegcetacoplan, intravitreal, 1 mg57020
Established patient complete exam of visual system524426
Established patient office or other outpatient visit, 30-39 minutes516386
Established patient office or other outpatient visit, 20-29 minutes290202
New patient complete exam of visual system135135

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 4 companies reported 4 payments worth $4,474 in total to this clinician.

By company
Astellas Pharma Global Development$4,400
Regeneron Healthcare Solutions, Inc.$39.33
Ocular Therapeutix, Inc.$19.54
Sandoz Inc.$15.34
By type
Consulting Fee$4,400
Food and Beverage$74.21

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Apr 3, 2025Astellas Pharma Global Development
Apr 3, 2025
Consulting Fee
Izervay · Ophthalmology
$4,400

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New York →

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $272,441 in research payments for these studies, mostly to the institutions running them.

  • Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration
    Ocular Therapeutix, Inc.
  • A Non-interventional, Observational Study to Evaluate Treatment Patterns and Safety of Avacincaptad Pegol (ACP/IZERVAY) in Routine Clinical Practice in Patients With Geographic Atrophy Secondary to Age-related Macular…
    Astellas Pharma Global Development
  • A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
    Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06541704
  • A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion
    Regeneron Pharmaceuticals, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Retina Specialist clinicians in Liverpool

Sources

NPI registry (CMS NPPES, November 2026; record last updated August 21, 2020), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1043576663. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.